Julian Downward
Affiliations: | Institute of Cancer Research, London, UK |
Area:
Cancer biologyWebsite:
https://www.crick.ac.uk/research/find-a-researcher/julian-downwardGoogle:
"(David) Julian (Harry) Downward" OR "Julian Downward"Bio:
https://www.icr.ac.uk/our-research/researchers-and-teams/professor-julian-downward
https://en.wikipedia.org/wiki/Julian_Downward
https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.691985
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Michael Derek Waterfield | grad student | 1986 | Imperial College London | |
| (The structure and function of the receptor for epidermal growth factor) | ||||
| Robert A. Weinberg | post-doc | 1986-1989 | MIT | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hill W, Lim EL, Weeden CE, et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature. 616: 159-167 |
| Zecchin D, Moore C, Michailidis F, et al. (2020) Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer. Embo Molecular Medicine. e11987 |
| Rodríguez-Martínez M, Boissiére T, Gonzalez MN, et al. (2020) Evidence That STK19 Is Not an NRAS-dependent Melanoma Driver. Cell. 181: 1395-1405.e11 |
| Wamaitha SE, Grybel KJ, Alanis-Lobato G, et al. (2020) IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche. Nature Communications. 11: 764 |
| Carné Sd, East P, Moore C, et al. (2020) Abstract B11: RAS orchestrates the increase of interstitial adenosine in lung adenocarcinoma to promote immune evasion Cancer Immunology Research. 8 |
| Jones GG, Rio IBD, Sari S, et al. (2020) Abstract B26: The SHOC2 phosphatase complex as a therapeutic target for ERK-pathway inhibition in RAS-driven tumors Molecular Cancer Research. 18 |
| Baer R, Rosewell I, Hancock D, et al. (2020) Abstract B19: New tools to study the role of RAS/CRAF interaction in RAS-driven lung cancer Molecular Cancer Research. 18 |
| Molina-Arcas M, Moore C, Rana S, et al. (2019) Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science Translational Medicine. 11 |
| Lionarons DA, Hancock DC, Rana S, et al. (2019) RAC1 Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. Cancer Cell |
| Liu H, Ertay A, Peng P, et al. (2019) SGLT1 is required for the survival of triple negative breast cancer cells via potentiation of EGFR activity. Molecular Oncology |